论文部分内容阅读
目的:研究特拉唑嗪联合索利那新治疗Ⅲ型前列腺炎的效果。方法:42例Ⅲ型前列腺炎患者纳入研究,年龄28-56岁,病程7月-2年,均有会阴区域疼痛、尿频及紧张、焦虑等症状。患者均采用特拉唑嗪联合索利那新治疗12周。在治疗前、治疗后4周和12周对患者进行前列腺炎症状(NIH-CPSI)评分并记录临床症状变化。结果:39例患者完成随访观察,其中显效25例(64.1%),有效9例(23.1%),症状无改善者5例(12.8%)。治疗12周后NIH-CPSI评分较治疗前有明显改善,平均降低13.2分(P<0.01)。结论:特拉唑嗪联合索利那新治疗Ⅲ型前列腺炎安全有效。
Objective: To study the effect of terazosin and solifenacin in the treatment of type Ⅲ prostatitis. Methods: Forty-two patients with type Ⅲ prostatitis were included in the study. The patients were 28-56 years of age and their duration of disease was from July to February. All patients had symptoms of perineal pain, urinary frequency, nervousness and anxiety. All patients were treated with terazosin plus solifenac for 12 weeks. Prostatitis symptoms (NIH-CPSI) scores were recorded before treatment, 4 weeks and 12 weeks after treatment, and the clinical symptoms were recorded. Results: Totally 39 patients were followed up, of which 25 (64.1%) were effective, 9 (23.1%) were effective and 5 (12.8%) were not improved. After 12 weeks of treatment, the NIH-CPSI score was significantly improved compared with that before treatment, with an average reduction of 13.2 points (P <0.01). Conclusion: Terazosin combined with Solifenacin is safe and effective in the treatment of type Ⅲ prostatitis.